Prostate Cancer Prevention: Concepts and Clinical Trials
- 664 Downloads
Prevention is an important treatment strategy for diminishing prostate cancer morbidity and mortality and is applicable to both early- and late-stage disease. There are three basic classifications of cancer prevention: primary (prevention of incident disease), secondary (identification and treatment of preclinical disease), and tertiary (prevention of progression or recurrence). Based on level I evidence, 5-alpha reductase inhibitors (5-ARIs) should be considered in selected men to prevent incident prostate cancer. Level I evidence also supports the consideration of dutasteride, a 5-ARI, for tertiary prevention in active surveillance and biochemical recurrence patients. Vitamins and supplements, including selenium or vitamin E, have not been proven in clinical trials to prevent prostate cancer and in the case of Vitamin E has been found to increase the risk of incident prostate cancer. Ongoing and future trials may further elucidate the role of diet and immunotherapy for prevention of prostate cancer.
KeywordsProstate cancer 5-Alpha reductase inhibitors Immunotherapy
Compliance with Ethical Standards
Conflict of Interest
Zachary Hamilton and J. Kellogg Parsons each declare no potential conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 8.Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y, et al. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate. 2006;66:1070–5.CrossRefPubMedGoogle Scholar
- 10.Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int. 2003;91:608–12.CrossRefPubMedGoogle Scholar
- 13.•Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301:39–51. This was a phase III trial with over 35,000 men examining natural substances (selenium and vitamin E) for chemoprevention of prostate cancer. After 7 years of follow up, no significant benefit was seen for either substance. With additional follow up, there was a small but significantly increased risk of prostate cancer in the vitamin E group. CrossRefPubMedPubMedCentralGoogle Scholar
- 19.•Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–24. This was a phase III trial evaluating the use of finasteride for prevention of prostate cancer over a 7 year follow up period. Over 18,000 men (at least 55 years old, PSA ≤ 3 ng/ml, normal DRE) were enrolled with for-cause biopsy or end-of-study biopsy performed. There was a 25 % relative risk reduction in prostate cancer detection associated with finasteride, although higher grade disease was diagnosed more frequently in the finasteride cohort. CrossRefPubMedGoogle Scholar
- 23.•Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192–202. This was a phase III trial evaluating the use of dutasteride for prevention of prostate cancer over a 4 year period. 8000 men (50–75 years old, PSA 2.5–10 ng/ml, negative prostate biopsy within 6 months of enrollment) were screened every 6 months with for-cause biopsy or planned biopsy at 2 and 4 years performed. There was a 23 % relative risk reduction associated with dutasteride and an increased incidence of high grade disease in the dutasteride cohort. This confirmed the findings of the PCPT trial. CrossRefPubMedGoogle Scholar
- 39.•Fleshner NE, Lucia MS, Egerdie B, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet. 2012;379:1103–11. This phase III trial evaluated the use of dutasteride in an active surveillance cohort, enrolling 302 men with low risk prostate cancer and following them over a 3 year period with planned biopsies performed at 1.5 and 3 years. There was a 38 % relative risk reduction in pathologic and therapeutic progression in the dutasteride cohort, although it was unclear if this was due to a true medication effect or instead due to reductions in patient/provider treatment anxiety given that dutasteride lowers PSA values and improves PSA operating characteristics. CrossRefPubMedGoogle Scholar
- 42.Schröder F, Bangma C, Angulo JC, et al. Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS). Eur Urol. 2013;63(5):779–87.CrossRefPubMedGoogle Scholar
- 51.Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007;11:1–160.Google Scholar